This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer
by Zacks Equity Research
Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).
Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs
by Zacks Equity Research
Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $136.39 in the latest trading session, marking a +1.12% move from the prior day.
AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate
by Zacks Equity Research
AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.
Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines
by Zacks Equity Research
Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J
by Zacks Equity Research
Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
by Zacks Equity Research
AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
by Zacks Equity Research
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Lilly (LLY) Inks Deal for Multiple Neurologic Indications
by Zacks Equity Research
Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.
Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug
by Kinjel Shah
FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.
Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc
by Zacks Equity Research
AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Top Analyst Reports for JPMorgan, Toyota & Netflix
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Toyota Motor Corp. (TM) and Netflix, Inc. (NFLX).
AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug
by Zacks Equity Research
AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $135.42, marking a +0.01% move from the previous day.
AbbVie (ABBV) Stock Moves -0.01%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $134.39, moving -0.01% from the previous trading session.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $132.05, moving +1.62% from the previous trading session.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe
by Zacks Equity Research
The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.
Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More
by Kinjel Shah
Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $131.78, moving +1.19% from the previous trading session.